

Adam Wilson, Lou Gehrig Day Committee Co-Chair, Cincinnati Reds Fan, Diagnosed with ALS in 2015:

"I have long been a fan of Lou Gehrig the player. Now, I'm also a fan of him as a man and as the namesake of my disease. I'm proud to represent him as well as the entire ALS community as Lou Gehrig Day becomes a permanent fixture on the MLB calendar!"

Chuck Haberstroh, Lou Gehrig Day Committee Co-Chair, Son of Patty Living with ALS, Boston Red Sox Fan:

"The most rewarding project of my life has been the lg4day initiative. I am so proud of what we've been able to accomplish thus far...but the best is yet to come: we will honor Lou Gehrig's legacy by finding cures and treatments to finally end ALS."

Tamara Hext Hilliard, Lou Gehrig Day Committee, Co-Founder of Team Hilliard ALS, Mom of Rockies OF Sam Hilliard, Colorado Rockies Fan:

"I am excited to see MLB continue to advocate for ALS and honor the great Lou Gehrig. As I care for my husband, Jim, I will continue to be involved with ALS awareness efforts and the quest for a cure, both locally and nationally. I am proud to say that the Colorado Rockies were the first team to support Lou Gehrig Day, back in October 2019!"

Mike Piscotty, Lou Gehrig Day Committee, President of ALS CURE Project, Dad of A's OF Stephen Piscotty:

"I believe Lou Gehrig's sentiments as he said, 'You don't get the breaks unless you play with the team instead of against it.' ALS is a curable disease if we work together in a coordinated manner to achieve breakthroughs following the collaboratively developed 'Roadmap to Cure ALS.' I look forward to the day when we have cured ALS and we celebrate Lou Gehrig the man, the leader and baseball player, and not Lou Gehrig who had the deadly ALS disease."

Brian Frederick, Ph.D., Lou Gehrig Day Committee, Senior Vice President of The ALS Association, Washington Nationals Fan:

"The people living with ALS, family members, and caregivers who have driven this campaign have inspired both the ALS and baseball communities. Thank you to Major League Baseball and all 30 teams for their efforts to help us strike out ALS. Baseball fans around the world will now learn more about Lou Gehrig, ALS, and this amazing community of people living with ALS and their loved ones."

Phil Green, Lou Gehrig Day Committee, Diagnosed with ALS in 2018, Seattle Mariners Fan:

"It has been an honor to be part of such a passionate team that has taken the dream of a Lou Gehrig Day and turned it into a reality. The LG4Day Committee learned from previous efforts for a Lou Gehrig Day and put together the Perfect Pitch to honor one of the greatest baseball players of all time while raising awareness of the incredibly cruel disease that shortened his career."

John and Nancy Frates:

"On the night of his ALS diagnosis, our son Pete set a vision. Part of that vision was to have MLB embrace one of its icons and the disease that took his life. So, today we celebrate. We celebrate Lou Gehrig, his amazing accomplishments and his inspiring legacy. We celebrate our ALS patients for their extraordinary courage and grace in the face of tremendous adversity. And we celebrate hope, hope for our ALS community, who by MLB's honor, continue to surround themselves with the hope that one day we will conquer this disease."



Pat Quinn Sr.:

"As a fierce advocate for ALS awareness, Pat was proud and honored to be an active supporter of plans for Lou Gehrig Day. We are pleased to see this celebration come to fruition, and we hope that this day across Major League Baseball will inspire everyone to come together in the fight against ALS."

Jon Sciambi, Chicago Cubs broadcaster with Marquee Sports Network and MLB Broadcaster with ESPN:

"As we honor one of the game's greatest players and men, we also continue the battle against ALS. I am so grateful to Major League Baseball for picking up this fight. Since losing my friend, Tim Sheehy, to ALS in 2007, this has been a very personal cause for me. I am all in for LG4Day."

Cal Ripken, Jr., Hall of Famer:

"I am thrilled that Major League Baseball is using its reach and influence to honor Lou's legacy while, at the same time, raising awareness of ALS and the need for a cure. Because of my streak, I have always been tied to Lou, and I always considered that to be a tremendous honor as he is one of the game's all-time greats. This is a wonderful initiative and I am proud to be a small part of it."

Jane Forbes Clark, Chairman, National Baseball Hall of Fame and Museum:

"For more than 80 years, Lou Gehrig's legacy has played a significant role in building the character of our National Pastime. The Museum has been entrusted with the preservation of this legacy through generous donations of important artifacts that bring to life, and preserve, his heroic performances, inspiring sportsmanship, and his unmatched legacy of incredible courage. We honor Lou Gehrig, not only in our Hall of Fame and throughout the Museum's exhibit areas, but also within our educational programming, where we use the example of his life to teach future generations important lessons of character."

ALS FACTS

- ALS is a fatal neurodegenerative disease that can strike anyone at any time. People with ALS lose the ability to control their muscles, which affects their ability to walk, talk, eat, and eventually breathe.
- ALS is a disease that attacks cells in the body that control movement. It makes the brain stop talking to the muscles, causing increased paralysis over time.
- Right now, there is no cure for ALS people who are diagnosed with it will die.
- ❖ There are an estimated 20,000-30,000 people living with ALS in the U.S.
- Every year, over 5,000 people are diagnosed with ALS and 5,000 people die from ALS.
- More than 60% of Americans know nothing about ALS, such as the fact that it is always fatal.
- ❖ Though the reasons aren't yet known, veterans are twice as likely to be diagnosed with ALS than non-veterans.

ALS RESEARCH FACTS

- Currently, there are only two drugs approved to treat ALS, though neither extends life in a significant way.
- ❖ In the U.S., there are currently at least 5 potential treatments in phase 3 trials and at least 15 in phase 2 trials.